Cargando…

Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer

INTRODUCTION: The addition of stereotactic ablative radiotherapy (SABR) to standard of care for patients with oligometastatic prostate cancer has the potential of improving survival and delaying further metastases. The primary aim of this analysis is to report survival outcomes and pattern of recurr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mercier, Carole, Claessens, Marc, De Troyer, Bart, Debacker, Tibaut, Fransis, Karen, Vandeursen, Hendrik, Ost, Piet, Dirix, Piet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046565/ https://www.ncbi.nlm.nih.gov/pubmed/35494057 http://dx.doi.org/10.3389/fonc.2022.863609

Ejemplares similares

A geometry and dose-volume based performance monitoring of artificial intelligence models in radiotherapy treatment planning for prostate cancer
por: De Kerf, Geert, et al.
Publicado: (2023)

Outcome and toxicity of hypofractionated image-guided SABR for spinal oligometastases
por: Billiet, Charlotte, et al.
Publicado: (2020)

Imaging modalities in synchronous oligometastatic prostate cancer
por: Futterer, Jurgen J., et al.
Publicado: (2018)

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
por: Hasan, Hamza, et al.
Publicado: (2020)

SABR in oligometastatic breast cancer: Current status and future directions
por: Stewart, Rachel, et al.
Publicado: (2021)

A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET)
por: Mercier, Carole, et al.
Publicado: (2019)

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
por: Decaestecker, Karel, et al.
Publicado: (2014)

Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience
por: Sánchez-Iglesias, Ángel L., et al.
Publicado: (2022)

Oligometastatic Prostate Cancer to the Navicular Bone: Case Report
por: Reyes, Diane K., et al.
Publicado: (2015)

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer
por: Ahmed, Kamran A., et al.
Publicado: (2013)

SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer
por: Azzam, Gregory, et al.
Publicado: (2015)

Accuracy and reliability of a commercial treatment planning system in nontarget regions in modern prostate radiotherapy
por: Danckaert, Willeke, et al.
Publicado: (2023)

Liquid Biopsy in Oligometastatic Prostate Cancer—A Biologist's Point of View
por: Stelcer, Ewelina, et al.
Publicado: (2019)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac
por: Janssen, Tomas M., et al.
Publicado: (2022)

Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
por: Katano, Atsuto, et al.
Publicado: (2021)

Radiotherapy for Oligometastatic Lung Cancer
por: Bergsma, Derek P., et al.
Publicado: (2017)

Is MRI-Linac helpful in SABR treatments for liver cancer?
por: Tallet, Agnès, et al.
Publicado: (2023)

Durable biochemical response following adrenal metastasectomy for oligometastatic castrate-resistant prostate cancer
por: Ashrafi, Akbar N., et al.
Publicado: (2020)

Testicular recurrence of oligometastatic prostatic adenocarcinoma after 22 years of androgen deprivation therapy
por: Fortier, Alexa, et al.
Publicado: (2022)

Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer
por: Alberto, Matthew, et al.
Publicado: (2022)

Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer
por: Bhattasali, Onita, et al.
Publicado: (2013)

Oligometastatic Adenocarcinoma of the Lung: A Therapeutic Opportunity for Long-Term Survival
por: Yarchoan, Mark, et al.
Publicado: (2015)

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial
por: Decaestecker, Karel, et al.
Publicado: (2014)

Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
por: Comito, Tiziana, et al.
Publicado: (2014)

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

Complete biochemical response following metastasis-directed radiotherapy for oligometastatic prostate cancer: A case report
por: Okuda, Satoshi, et al.
Publicado: (2020)

On the reduction of aperture complexity in kidney SABR
por: Gaudreault, Mathieu, et al.
Publicado: (2021)

Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread
por: Batich, Kristen A., et al.
Publicado: (2019)

Oligometastatic Disease Management: Finding the Sweet Spot
por: Szturz, Petr, et al.
Publicado: (2020)

Oligometastatic Prostate Cancer
por: Stevens, Daniel J., et al.
Publicado: (2016)

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
por: Palma, David A., et al.
Publicado: (2020)

Metastasis-directed therapy: a new standard for oligorecurrent prostate cancer?
por: Zilli, Thomas, et al.
Publicado: (2018)

Multimodal therapy in urachal carcinoma with oligometastatic bone disease
por: García Alvarez, C., et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease
por: Mehrens, Dirk, et al.
Publicado: (2021)

The Prognostic Value of Liquid Biopsies for Benefit of Salvage Radiotherapy in Relapsed Oligometastatic Prostate Cancer
por: Bogdanova, Natalia V., et al.
Publicado: (2022)

Does Pathologic Response Equate to Clinical Response Following SABR for Early-Stage NSCLC?
por: Brooks, Eric D., et al.
Publicado: (2019)

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
por: Palma, David A, et al.
Publicado: (2012)

Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases
por: Mazzola, Rosario, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nv7epbmg93ksuoqrhmr6hj9e8s